Dopamine receptor D1 and D2 subtypes (DRD1/2)

Dopamine receptors D1 (DRD1) and D2 (DRD2) are prominent G protein-coupled receptors that mediate the diverse actions of dopamine in the central nervous system and other tissues. DRD1, primarily coupled to Gs proteins, activates adenylyl cyclase to increase intracellular cAMP, playing a crucial role in motor activity, reward, and cognition. DRD2, mainly coupled to Gi/o proteins, inhibits adenylyl cyclase to decrease intracellular cAMP, essential for motor control, reward, and neuroendocrine regulation. Together, these two receptor subtypes are the most abundant and therapeutically relevant dopamine receptors in the brain, implicated in various neuropsychiatric and neuroendocrine conditions, including Parkinson disease, schizophrenia, and addiction. Their distinct signaling pathways and anatomical distributions allow for complex modulation of dopaminergic neurotransmission, making them key targets for numerous therapeutic agents.

Other names

D1 receptorDRD1Dopamine D1 receptorD2 receptorDRD2Dopamine D2 receptorDopamine D1 and D2 receptors

Dopamine receptor D1 (DRD1) agonists activate adenylyl cyclase via Gs protein coupling, increasing cAMP production, while antagonists block dopamine-mediated activation, reducing downstream signaling. Dopamine receptor D2 (DRD2) agonists inhibit adenylyl cyclase via Gi/o protein coupling, reducing cAMP production, and antagonists block these inhibitory effects, leading to increased dopaminergic tone, commonly targeted by antipsychotics.